{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:32:46Z","timestamp":1784734366934,"version":"3.55.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":2699,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s13311-016-0420-z","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T09:39:16Z","timestamp":1454924356000},"page":"428-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-\u03b21a and Circulating Proinflammatory Cytokines in Relapsing\u2013Remitting Multiple Sclerosis"],"prefix":"10.1016","volume":"13","author":[{"given":"Nicola S.","family":"Orefice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Alhouayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Montella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franscesco","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Comelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Calignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio G.","family":"Muccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Orefice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0420-z_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0929-7855(96)00510-X","article-title":"Membrane localization of N-acylphosphatidylethonolamine in central neurons: studies with exogenous phospholipases","volume":"14","author":"Cadas","year":"1996","journal-title":"J. Lipid Mediat Cell Signal"},{"key":"10.1007\/s13311-016-0420-z_bib2","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.drudis.2014.06.007","article-title":"Harnessing the anti-inflammatory potential of palmitoylethanolamide","volume":"19","author":"Alhouayek","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1007\/s13311-016-0420-z_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/28393","article-title":"Control of pain initiation by endogenous cannabinoids","volume":"394","author":"Calignano","year":"1998","journal-title":"Nature"},{"key":"10.1007\/s13311-016-0420-z_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(01)00988-8","article-title":"Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide","volume":"419","author":"Calignano","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-016-0420-z_bib5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/jpet.106.111385","article-title":"Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha","volume":"319","author":"Lo Verme","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-016-0420-z_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1528-1157.2001.41499.x","article-title":"Anticonvulsant activity of N-palmitoylethanolamine, a putative endocannabinoid, in mice","volume":"42","author":"Lambert","year":"2001","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-016-0420-z_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041880","article-title":"Neuroprotective activities of palmitoylethanolamide in an animal model of parkinson's disease","volume":"7","author":"Esposito","year":"2012","journal-title":"Plos One"},{"key":"10.1007\/s13311-016-0420-z_bib8","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/npp.2012.25","article-title":"Palmitoylethanolamide protects against the amyloid-\u03b225-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease","volume":"37","author":"D'Agostino","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-016-0420-z_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2999(96)00015-5","article-title":"N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation","volume":"300","author":"Mazzari","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-016-0420-z_bib10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbi.2011.02.006","article-title":"Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury","volume":"25","author":"Esposito","year":"2011","journal-title":"Brain Behav Immun"},{"key":"10.1007\/s13311-016-0420-z_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/mol.104.006353","article-title":"The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide","volume":"67","author":"Lo Verme","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1007\/s13311-016-0420-z_bib12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/jpet.107.123265","article-title":"Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice","volume":"322","author":"D'Agostino","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-016-0420-z_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2009.04.022","article-title":"Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signaling in dorsal root ganglia","volume":"613","author":"D'Agostino","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-016-0420-z_bib14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.lfs.2005.05.012","article-title":"The search for the palmitoylethanolamide receptor","volume":"77","author":"Lo Verme","year":"2005","journal-title":"Life Sci"},{"key":"10.1007\/s13311-016-0420-z_bib15","doi-asserted-by":"crossref","first-page":"20966","DOI":"10.1073\/pnas.0907417106","article-title":"Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation","volume":"106","author":"Solorzano","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-016-0420-z_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0420-z_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2009.01.012","article-title":"Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging","volume":"282","author":"Chard","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-016-0420-z_bib18","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.neuroimage.2008.06.028","article-title":"Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study","volume":"42","author":"Calabrese","year":"2008","journal-title":"Neuroimage"},{"key":"10.1007\/s13311-016-0420-z_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM198708133170703","article-title":"Slagle S, et al A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis","volume":"317","author":"Bornstein","year":"1987","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-016-0420-z_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0420-z_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-016-0420-z_bib22","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1007\/s13311-016-0420-z_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/21548331.2001.11444101","article-title":"Current therapy of multiple sclerosis","volume":"36","author":"Johnson","year":"1995","journal-title":"Hosp. Pract."},{"key":"10.1007\/s13311-016-0420-z_bib24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","article-title":"Multiple sclerosis: side effects of interferon beta therapy and their management","volume":"53","author":"Walther","year":"1999","journal-title":"Neurology."},{"key":"10.1007\/s13311-016-0420-z_bib25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","volume":"59","author":"Panitch","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0420-z_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jns.2013.05.031","article-title":"Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate","volume":"331","author":"Carotenuto","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1007\/s13311-016-0420-z_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1460-9568.2008.06377.x","article-title":"Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide","volume":"287","author":"Loria","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1007\/s13311-016-0420-z_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1007\/s13311-016-0420-z_bib29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0420-z_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Qual. Life Res."},{"key":"10.1007\/s13311-016-0420-z_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/13803390701779560","article-title":"Information-processing speed is the primary deficit underlying the poor performance of multiple sclerosis patients in the Paced Auditory Serial Addition Test (PASAT)","volume":"30","author":"Forn","year":"2008","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"10.1007\/s13311-016-0420-z_bib32","first-page":"140","article-title":"Paced visual serial addition test: an alternative measure of information processing speed","volume":"7","author":"Fos","year":"2000","journal-title":"Neuropsychology."},{"key":"10.1007\/s13311-016-0420-z_bib33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nrl.2010.07.014","article-title":"Ramo-Tello C Analysis of the pain in multiple sclerosis patients","volume":"26","author":"Grau-L\u00f3pez","year":"2011","journal-title":"Neurologia."},{"key":"10.1007\/s13311-016-0420-z_bib34","doi-asserted-by":"crossref","first-page":"17558","DOI":"10.1073\/pnas.1314017110","article-title":"Muccioli GG Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6","volume":"110","author":"Alhouayek","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1007\/s13311-016-0420-z_bib35","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.drudis.2010.03.007","article-title":"Endocannabinoid biosynthesis and inactivation, from simple to complex","volume":"15","author":"Muccioli","year":"2010","journal-title":"Drug Discov. Today."},{"key":"10.1007\/s13311-016-0420-z_bib36","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1073\/pnas.161191698","article-title":"Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase","volume":"98","author":"Cravatt","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1007\/s13311-016-0420-z_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem. Biol."},{"key":"10.1007\/s13311-016-0420-z_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbalip.2005.08.010","article-title":"Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages","volume":"1736","author":"Sun","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1007\/s13311-016-0420-z_bib39","first-page":"1274","article-title":"Enzymological studies on the biosynthesis of N-acylethanolamines","volume":"2010","author":"Ueda","year":"1801","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1007\/s13311-016-0420-z_bib40","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.2174\/138161208785740018","article-title":"The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases","volume":"14","author":"Centonze","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1007\/s13311-016-0420-z_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pain.2007.08.024","article-title":"Pain associated with multiple sclerosis: systematic review and proposed classification","volume":"137","author":"O'Connor","year":"2008","journal-title":"Pain"},{"issue":"5","key":"10.1007\/s13311-016-0420-z_bib42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.pain.2012.12.002","article-title":"Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis","volume":"154","author":"Foley","year":"2013","journal-title":"Pain"},{"key":"10.1007\/s13311-016-0420-z_bib43","first-page":"35","article-title":"La palmitoiletanolamida (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. [Palmitoylethanolamide treatment of sciatic pain: results form a multicenter study]","volume":"25","author":"Guida","year":"2010","journal-title":"Dolor"},{"key":"10.1007\/s13311-016-0420-z_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/JPR.S32143","article-title":"Hekker TA Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series","volume":"5","author":"Hesselink","year":"2012","journal-title":"J Pain Res."},{"issue":"3","key":"10.1007\/s13311-016-0420-z_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-2999(00)00059-5","article-title":"Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice","volume":"392","author":"Hao","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-016-0420-z_bib46","doi-asserted-by":"crossref","first-page":"16676","DOI":"10.1038\/srep16676","article-title":"Co-ultramicronized palmitoylethanolamide\/luteolin promotes the maturation of oligodendrocyte precursor cells","volume":"5","author":"Barbierato","year":"2015","journal-title":"Sci Rep."},{"key":"10.1007\/s13311-016-0420-z_bib47","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bcp.2015.02.012","article-title":"Chronic oleoylethanolamide treatment improves spatial cognitive deficits through enhancing hippocampal neurogenesis after transient focal cerebral ischemia","volume":"94","author":"Yang","year":"2015","journal-title":"Biochem Pharmacol."},{"key":"10.1007\/s13311-016-0420-z_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.it.2011.02.007","article-title":"IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease","volume":"32","author":"Zepp","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1007\/s13311-016-0420-z_bib49","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.2815","article-title":"The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-\u03b1","volume":"18","author":"Zhu","year":"2012","journal-title":"Nat. Med."},{"key":"10.1007\/s13311-016-0420-z_bib50","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/glia.22307","article-title":"Regulation of CCL20 expression in astrocyte by IL-6 and IL-17","volume":"60","author":"Meares","year":"2012","journal-title":"Glia"},{"key":"10.1007\/s13311-016-0420-z_bib51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity."},{"key":"10.1007\/s13311-016-0420-z_bib52","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/eji.200838879","article-title":"Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T cells in MS","volume":"39","author":"Chen","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1007\/s13311-016-0420-z_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2009.05.019","article-title":"Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1","volume":"133","author":"Christophi","year":"2009","journal-title":"Clin Immunol."},{"key":"10.1007\/s13311-016-0420-z_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasone activation","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity."},{"key":"10.1007\/s13311-016-0420-z_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2004.09.002","article-title":"The pathology of multiple sclerosis","volume":"23","author":"Lucchinetti","year":"2005","journal-title":"Neurol Clin"},{"key":"10.1007\/s13311-016-0420-z_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1750-3639.2005.tb00523.x","article-title":"Multiple sclerosis pathology: evolution of pathogenetic concepts","volume":"15","author":"Lassmann","year":"2005","journal-title":"Brain Pathol."},{"key":"10.1007\/s13311-016-0420-z_bib57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-016-0420-z_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jns.2008.04.003","article-title":"Mechanisms of inflammation induced tissue injury in multiple sclerosis","volume":"274","author":"Lassmann","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1007\/s13311-016-0420-z_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039186","article-title":"Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease","volume":"7","author":"D'Addario","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-016-0420-z_bib60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2013.07.020","article-title":"Progesterone reverts LPS-reduced FAAH activity in murine peripheral blood mononuclear cells by a receptor-mediated fashion","volume":"381","author":"Wolfson","year":"2013","journal-title":"Mol Cell Endocrinol."},{"key":"10.1007\/s13311-016-0420-z_bib61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1871527311312010011","article-title":"Neuroglial roots of neurodegenerative disease: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease","volume":"12","author":"Scuderi","year":"2013","journal-title":"CNS Neurol Disorder Drug Target"},{"key":"10.1007\/s13311-016-0420-z_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neuron.2005.11.027","article-title":"The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells","volume":"49","author":"Eljaschewitsch","year":"2006","journal-title":"Neuron."},{"key":"10.1007\/s13311-016-0420-z_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2008.09.014","article-title":"A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells","volume":"77","author":"Correa","year":"2009","journal-title":"Biochem Pharmacol."},{"key":"10.1007\/s13311-016-0420-z_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0014-5793(01)02934-9","article-title":"Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors","volume":"506","author":"De Petrocellis","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1007\/s13311-016-0420-z_bib65","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0959-4388(02)00340-9","article-title":"Endovanilloid signaling in pain","volume":"12","author":"Di Marzo","year":"2002","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1007\/s13311-016-0420-z_bib66","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1007\/s13311-016-0420-z_bib67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"10.1007\/s13311-016-0420-z_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2006.02.004","article-title":"Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents","volume":"3","author":"Overton","year":"2006","journal-title":"Cell Metab."},{"key":"10.1007\/s13311-016-0420-z_bib69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.00-0399fje","article-title":"Endocannabinoids control spasticity in a multiple sclerosis model","volume":"15","author":"Baker","year":"2001","journal-title":"FASEB J."},{"key":"10.1007\/s13311-016-0420-z_bib70","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental Parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1007\/s13311-016-0420-z_bib71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuint.2007.06.031","article-title":"Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6\/2 mice, a transgenic model of Huntington's disease","volume":"52","author":"Bisogno","year":"2008","journal-title":"Neurochem Int."},{"key":"10.1007\/s13311-016-0420-z_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2012.03.008","article-title":"Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor \u03b1","volume":"63","author":"Zhou","year":"2012","journal-title":"Neuropharmacol."},{"key":"10.1007\/s13311-016-0420-z_bib73","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1017\/S1461145713001259","article-title":"The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism","volume":"17","author":"Gonzalez-Aparicio","year":"2014","journal-title":"Int J Neuropsychopharmacol."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0420-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923015970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0420-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:08:20Z","timestamp":1761808100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923015970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1878747923015970"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0420-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-\u03b21a and Circulating Proinflammatory Cytokines in Relapsing\u2013Remitting Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0420-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}